Aurobindo – Recall of quinapril/hydrochlorothiazide
October 25, 2022 - The FDA announced a consumer level recall of two lots of Aurobindo’s quinapril/hydrochlorothiazide (HCTZ) 20 mg/12.5 mg tablets due to the presence of nitrosamine drug substance related impurity (NDSRI), N-Nitroso-Quinapril, above the proposed interim limit.
Top